Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial

- Siva, Shankar, Bressel, Mathias, Lin, Charles, Raman, Avi, Hardcastle, Nicholas, Hofman, Michael S., De Abreu Lourenco, Richard, Shaw, Mark, Mancuso, Pascal, Moon, Daniel, Wong, Lih-Ming, Lawrentschuk, Nathan, Sidhom, Mark, Wood, S, Brook, NR, Kron, T, Martin, Jarad, Pryor, D, FASTRACK II Investigator Group,, Sridharan, Swetha, Vanneste, Ben G. L., Davey, Ryan, Montgomery, Rebecca, Ruben, Jeremy, Foroudi, Farshad, Higgs, Braden

Genitourinary Quality-of-Life Comparison Between Urethral Sparing Prostate Stereotactic Body Radiation Therapy Monotherapy and Virtual High-Dose-Rate Brachytherapy Boost

- Richardson, Matthew, Sidhom, Mark, Pryor, David, Siva, Shankar, Martin, Jarad, Keall, Paul, Leigh, Lucy, Ball, Helen, Bucci, Joseph, Gallagher, Sarah, Greer, Peter, Hayden, Amy J., Kneebone, Andrew

SEAFARER – A new concept for validating radiotherapy patient specific QA for clinical trials and clinical practice: SEAFARER - sensitivity of patient specific quality assurance, PSQA

- Lehmann, Joerg, Hussein, Mohammad, Claridge Mackonis, Elizabeth, Meehan, Carole, Patel, Rushil, Ray, Xenia, Shaw, Maddison, Shepherd, Justin, Smyth, Gregory, Standen, Therese S., Subramanian, Brindha, Greer, Peter B., Barry, Miriam A., Clark, Catharine H., Siva, Shankar, Moore, Alisha, Chu, Michael, Díez, Patricia, Eaton, David J., Harwood, Jeffrey, Lonski, Peta

Credentialing of vertebral stereotactic ablative body radiotherapy in a multi-centre trial

- Hardcastle, Nicholas, Kron, Tomas, Cook, Olivia, Lehmann, Joerg, Mitchell, Paul L. R., Siva, Shankar

Extracranial oligometastatic renal cell carcinoma: current management and future directions

- Loh, Jasmin, Davis, Ian D., Martin, Jarad M., Siva, Shankar